logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
C

Chadi Hage Chehade

Utah System of Higher Education
H指数:7
被引数:165

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials

种族与接受阿帕鲁他胺治疗患者生存期的关联：两项III期试验的合并分析

Cancer
IF5.1
2026-01-010
PRE
Gebrael, Georges; Agarwal, Neeraj; Morgans, Alicia K.; Vince, Randy; Swami, Umang; Jia, Angela Y.; Zaorsky, Nicholas; Chehade, Chadi Hage; Ozay, Zeynep Irem; Malone, Shawn; Morgan, Scott C.; Wallis, Christopher J. D.; Kishan, Amar U.; Barata, Pedro C.; Chowdhury, Simon; Garcia, Jorge A.; Sheng, Iris; Brown, Jason R.; Small, Eric J.; Sun, Yilun; Shore, Neal D.; Saad, Fred; Spratt, Daniel E.; Roy, Soumyajit
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy

接受强化雄激素剥夺治疗的转移性激素敏感性前列腺癌患者生存的基因组生物标志物

PROSTATE CANCER AND PROSTATIC DISEASES
IF5.8
2025-01-310
PRE
Gebrael, Georges; Sayegh, Nicolas; Chehade, Chadi Hage; Jo, Yeonjung; Narang, Arshit; Chigarira, Beverly; Tripathi, Nishita; Srivastava, Ayana; Tandar, Clara; Williams, Jessica F.; Garg, Diya; Ji, Richard; Maughan, Benjamin L.; Swami, Umang; Agarwal, Neeraj
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix

使用鲁格利克间歇性雄激素剥夺疗法治疗的晚期前列腺癌患者的睾酮抑制与恢复

THERAPEUTIC ADVANCES IN UROLOGY
IF3.5
2024-11-080
OA
Campbell, Patrick; Gebrael, Georges; Narang, Arshit; Chehade, Chadi Hage; Thomas, Vinay Mathew; Fortuna, Gliceida Galarza; Sayegh, Nicolas; Tripathi, Nishita; Tandar, Clara; Dal, Emre; Li, Haoran; Swami, Umang; Agarwal, Neeraj; Maughan, Benjamin L.
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216

体重指数与转移性激素敏感性前列腺癌患者总生存期的相关性：SWOG-1216患者层面数据分析

European Urology Oncology
IF9.3
2024-11-010
PRE
Umang Swami; Yeonjung Jo; Arshit Narang; Melissa Plets; Chadi Hage Chehade; Georges Gebrael; Shilpa Gupta; Zin Myint; Catherine Tangen; Primo N. Lara; Ian M. Thompson; Maha H.A. Hussain; Tanya B. Dorff; Seth P. Lerner; Neeraj Agarwal
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
CANCER
IF5.1
2024-04-020
OAAI
Gebrael, Georges; Jo, Yeonjung; Thomas, Vinay Mathew; Li, Haoran; Sayegh, Nicolas; Tripathi, Nishita; Srivastava, Ayana; Nordblad, Blake; Dal, Emre; Narang, Arshit; Brundage, James; Campbell, Patrick; Fortuna, Gliceida Galarza; Chehade, Chadi Hage; Maughan, Benjamin L.; Agarwal, Neeraj; Swami, Umang
Tumor genomic and transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus do not achieve an optimal PSA response to androgen deprivation therapy intensification (ADTi)
CANCER RESEARCH
IF16.6
2024-03-220
PRE
Thomas, Vinay Mathew; Chigarira, Beverly; Gebrael, Georges; Chehade, Chadi; Narang, Arshit; Sayegh, Nicolas; Tripathi, Nishita; Jo, Yeonjung; Tandar, Clara; Srivastava, Ayana; Ji, Richard; Dal, Emre; Fortuna, Gliceida Galarza; Li, Haoran; Maughan, Benjamin L.; Swami, Umang; Agarwal, Neeraj
Comparative real-world effectiveness of PD-1/L1 inhibitor (PD-1i) plus cabozantinib (cabo) vs cabo after progression with prior immune checkpoint inhibitor (ICI) treatment (Rx) in metastatic clear cell renal cell carcinoma (mccRCC)
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Swami, U.; Jo, Y. Jung; Thomas, V. Mathew; Gebrael, G.; Li, H.; Sayegh, N.; Tripathi, N.; Srivastava, A.; Nordblad, B.; Dal, E.; Brundage, J.; Campbell, P.; Fortuna, G. Galarza; Chehade, C. Hage; Maughan, B. L.; Agarwal, N.
Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab plus nivolumab (ipi plus nivo) vs. PD-1/L1 inhibitor (PDI) plus tyrosine kinase inhibitor (TKI)
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
PRE
Gebrael, G.; Jo, Y. Jung; Thomas, V. Mathew; Li, H.; Fortuna, G. Galarza; Sahu, K.; Sayegh, N.; Tripathi, N.; Chigarira, B.; Srivastava, A.; Chehade, C. Hage; Nordblad, B.; Dal, E.; Brundage, J.; Maughan, B. L.; Agarwal, N.; Swami, U.

研究方向

暂未获取到该数据
G
Georges Gebrael
H 指数:10论文数:146被引数:467
N
Neeraj Agarwal
H 指数:6论文数:45被引数:637
U
Umang Swami
H 指数:27论文数:417被引数:3,167
N
Nicolas Sayegh
H 指数:17论文数:199被引数:1,875
B
Benjamin L. Maughan
H 指数:29论文数:393被引数:3,288
Y
Yeonjung Jo
H 指数:9论文数:117被引数:603
B
Beverly Chigarira
H 指数:5论文数:75被引数:185
N
Nishita Tripathi
H 指数:13论文数:126被引数:560
G
Gliceida Galarza Fortuna
H 指数:8论文数:92被引数:289
A
Arshit Narang
H 指数:6论文数:31被引数:124